MDT

88.96

+0.59%ā†‘

VEEV

226.47

-0.52%ā†“

A

115.98

+2.05%ā†‘

HQY

88.73

+1.89%ā†‘

PDCO

31.27

+0.06%ā†‘

MDT

88.96

+0.59%ā†‘

VEEV

226.47

-0.52%ā†“

A

115.98

+2.05%ā†‘

HQY

88.73

+1.89%ā†‘

PDCO

31.27

+0.06%ā†‘

MDT

88.96

+0.59%ā†‘

VEEV

226.47

-0.52%ā†“

A

115.98

+2.05%ā†‘

HQY

88.73

+1.89%ā†‘

PDCO

31.27

+0.06%ā†‘

MDT

88.96

+0.59%ā†‘

VEEV

226.47

-0.52%ā†“

A

115.98

+2.05%ā†‘

HQY

88.73

+1.89%ā†‘

PDCO

31.27

+0.06%ā†‘

MDT

88.96

+0.59%ā†‘

VEEV

226.47

-0.52%ā†“

A

115.98

+2.05%ā†‘

HQY

88.73

+1.89%ā†‘

PDCO

31.27

+0.06%ā†‘

Search

Alvotech SA

Gesloten

SectorGezondheidszorg

9.22 -3.86

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

9.11

Max

9.3

Belangrijke statistieken

By Trading Economics

Inkomsten

-56M

-67M

Verkoop

48M

151M

EPS

-0.24

Winstmarge

-44.289

Werknemers

1,012

EBITDA

155M

138M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+107.47% upside

Dividenden

By Dow Jones

Volgende Winsten

20 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-572M

2.9B

Vorige openingsprijs

13.08

Vorige sluitingsprijs

9.22

Nieuwssentiment

By Acuity

50%

50%

180 / 386 Rangschikking in Healthcare

Alvotech SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 mei 2024, 20:30 UTC

Top Nieuws

Teva Earnings Are Soon. What Could Keep the Stock Gains Going. -- Barrons.com

Peer Vergelijking

Prijswijziging

Alvotech SA Prognose

Koersdoel

By TipRanks

107.47% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 20Ā USDĀ  107.47%

Hoogste 28Ā USD

Laagste 14Ā USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Alvotech SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Sentiment

By Acuity

180 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Alvotech SA

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.